Bioprocessing

Are Bioengineered Vessels the Future of Vascular Surgery?
Biotech & Bioprocessing Are Bioengineered Vessels the Future of Vascular Surgery?

Trauma surgeons often face a race against time when a patient presents with a shattered limb or a ruptured artery where every second spent searching for a viable donor vein increases the risk of amputation or death. This high-pressure environment has long necessitated a surgical solution that

Imugene’s Azer-cel Shows Promise in Resistant Lymphoma
Research & Development Imugene’s Azer-cel Shows Promise in Resistant Lymphoma

The clinical landscape of modern oncology is undergoing a profound transformation as biotechnology firms successfully engineer specialized immune cells to target and eliminate aggressive blood cancers that have developed a resistance to conventional medical interventions. Imugene Limited, a

Can SpudCell Revolutionize How We Engineer Synthetic Life?
Biotech & Bioprocessing Can SpudCell Revolutionize How We Engineer Synthetic Life?

The recent emergence of SpudCell represents a profound shift in biotechnological history, effectively moving beyond the mere observation of life to the construction of a self-sustaining autonomous entity. Developed by dedicated researchers at the University of Minnesota, this first-of-its-kind

Trial Strategy Is Key for Spinal Cord Injury Cell Therapy
Biotech & Bioprocessing Trial Strategy Is Key for Spinal Cord Injury Cell Therapy

The scientific pursuit of restoring motor and sensory function to patients suffering from traumatic spinal cord injuries has recently transitioned from a purely exploratory endeavor into a rigorous exercise in clinical trial strategy and logistical precision. While the biological potential of

Top 26 Companies Leading Sustainable Biopharma in 2026
Research & Development Top 26 Companies Leading Sustainable Biopharma in 2026

The global biopharmaceutical industry has arrived at a definitive juncture where the preservation of the planet is no longer viewed as a peripheral corporate social responsibility goal but as a core requirement for therapeutic efficacy and long-term business resilience. As we navigate the current

Airlift Bioreactors Market to Reach $8.2 Billion by 2035
Biotech & Bioprocessing Airlift Bioreactors Market to Reach $8.2 Billion by 2035

The global biopharmaceutical landscape is currently undergoing a transformative phase where the demand for precision-engineered therapeutic proteins and complex cellular products has outpaced the capabilities of traditional fermentation systems. This shift is most evident in the rapid adoption of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later